KMT2A and leukemia: Using a murine MLL‐AF9 AML model, blocking CXCR4 was found to reduce Treg accumulation in the leukaemia haematopoietic microenvironment and promote anti‐leukaemic effects of CD8+ T cells, and delay leukaemia progression.85